Virtual care company’s Q3 performance disappoints
- Teladoc’s stock tumbles 5.8% after missing sales estimates
- Company posts narrower-than-expected loss for Q3
- Revenue falls short of estimates, up 8% to $660.2 million
- Full-year guidance also lags consensus
- Stock down 23% YTD
Factuality Level: 8
Justification: The article provides specific financial figures and compares them to previous periods and analyst estimates. It does not contain any irrelevant or misleading information, sensationalism, redundancy, or opinion masquerading as fact. The information provided is objective and based on factual data.
Noise Level: 3
Justification: The article provides relevant information about Teladoc Health Inc.’s stock performance and financial results for the third quarter. It includes details about the company’s net loss, revenue, and guidance for the full year. However, it lacks in-depth analysis, scientific rigor, and actionable insights. The article also does not explore the consequences of the company’s performance on stakeholders or hold powerful people accountable.
Financial Relevance: Yes
Financial Markets Impacted: Teladoc Health Inc.
Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article pertains to the financial performance of Teladoc Health Inc., a virtual care company. It discusses the company’s third-quarter results, including a narrower-than-expected loss and revenue that fell short of estimates. The stock price of Teladoc Health Inc. tumbled in after-hours trading as a result of the earnings report.
Public Companies: Teladoc Health Inc. (TDOC)
Private Companies:
Key People:
Teladoc Health Inc.’s stock tumbled 5.8% in after-hours trading after the company reported a narrower-than-expected loss for the third quarter but fell short of revenue estimates. The net loss for the quarter was $57.1 million, or 35 cents a share, compared to $73.5 million, or 45 cents a share, in the same period last year. Revenue increased by 8% to $660.2 million. However, the company’s full-year guidance also fell below consensus. Teladoc expects a fourth-quarter loss of 33 cents to 23 cents a share and revenue of $658 million to $683 million. The stock has declined by 23% year-to-date, while the S&P 500 has gained 10.6%.
